

Emergence and spread of feline infectious peritonitis due to a highly pathogenic canine/feline recombinant coronavirus

Charalampos Attipa^{1,2◇*}, Amanda S Warr^{2◇*}, Demetris Epaminondas³, Marie O'Shea², Sarah Fletcher², Alexandra Malbon^{2,3}, Maria Lyraki⁴, Rachael Hammond¹, Alexandros Hardas⁵, Antria Zanti⁶, Stavroula Loukaidou⁶, Michaela Gentil⁷, Danielle Gunne-Moore¹, Stella Mazeri², Christine Tait-Burkard^{2*}

¹Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Midlothian, United Kingdom.

²The Roslin Institute, Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Midlothian, United Kingdom.

³Veterinary Services, Ministry of Agriculture, Natural Resources and Environment, Cyprus.

⁴Plakentia Veterinary Clinic, Athens, Greece.

⁵Department of Pathobiology and Population Sciences, Royal Veterinary College, Hatfield, Hertfordshire.

⁶Vet Dia Gnosis Ltd, Limassol, Cyprus.

⁷Laboklin GmbH and Co KG, Bad Kissingen, Germany.

◇Contributed equally to this work. CA was responsible for epidemiology, pathology and sample/outbreak data collection. AW performed sequencing and data analysis thereof. Both are equally important but the latter couldn't have happened without the first.

*Corresponding authors

Email: charalampos.attipa@ed.ac.uk

Email: Amanda.warr@roslin.ed.ac.uk

Email: christine.burkard@roslin.ed.ac.uk

30 **Abstract**

31 Cross-species transmission of coronaviruses (CoVs) poses a serious threat to both animal and
32 human health¹⁻³. Whilst the large RNA genome of CoVs shows relatively low mutation rates,
33 recombination within genera is frequently observed and demonstrated⁴⁻⁷. Companion animals
34 are often overlooked in the transmission cycle of viral diseases; however, the close relationship
35 of feline (FCoV) and canine CoV (CCoV) to human hCoV-229E^{5,8}, as well as their susceptibility to
36 SARS-CoV-2⁹ highlight their importance in potential transmission cycles. Whilst recombination
37 between CCoV and FCoV of a large fragment spanning orf1b to M has been previously
38 described^{5,10}, here we report the emergence of a novel, highly pathogenic FCoV-CCoV
39 recombinant responsible for a rapidly spreading outbreak of feline infectious peritonitis (FIP),
40 originating in Cyprus¹¹. The recombination, spanning spike, shows 97% sequence identity to the
41 pantropic canine coronavirus CB/05. Infection is spreading fast and infecting cats of all ages.
42 Development of FIP appears rapid and likely non-reliant on biotype switch¹². High sequence
43 identity of isolates from cats in different districts of the island is strongly supportive of direct
44 transmission. A deletion and several amino acid changes in spike, particularly the receptor
45 binding domain, compared to other FCoV-2s, indicate changes to receptor binding and likely cell
46 tropism.

47 **Main**

48 Following two epidemics, SARS-CoV 2002-4 and MERS-CoV 2012-ongoing, and a pandemic of
49 previously unseen proportions, SARS-CoV-2 2019 onwards, coronaviruses no longer need
50 lengthy introductions of importance and scale. They are not only present in the human
51 population, they are also in wildlife¹³⁻¹⁵, companion animals¹⁶⁻¹⁹ and livestock^{13,20,21}, and in all
52 species these viruses have major impacts. The innate ability of coronaviruses to recombine with
53 other coronaviruses continues to fuel their species-switching ability. It is therefore not surprising
54 that both human and animal coronaviruses are linked in complex transmission and evolution
55 cycles^{3,14,19,22}.


56 FCoV is found across the globe. The virus exists in two biotypes with the main biotype, feline
57 enteric coronavirus (FECV), showing low virulence and clinical signs are typically limited to mild
58 enteritis. The second biotype of FCoV, proposed to originate each time from a mutation in an
59 FECV-infected cat (reviewed in ²³), is known as feline infectious peritonitis virus (FIPV). FIPV
60 causes feline infectious peritonitis (FIP), which is a fatal disease if left untreated. Clinical signs
61 include an abdomen swollen due to peritoneal fluid, fever, weight loss lethargy, anorexia,
62 dyspnoea, ocular abnormalities and neurological signs^{8,16,24,25}. Mutations in the spike gene or the
63 accessory genes 3abc and of 7ab of FCoV^{8,16,23,26} are thought to result in changes to the virus's
64 tropism from cells in the enteric tract to macrophages, resulting in the different disease

65 presentation seen with the two biotypes. This change in primary tropism also impacts the virus's
66 ability to transmit from cat to cat, with the main transmission pathway of FECV being faecal-oral
67 and FIPV typically having relatively poor transmission potential. Antivirals, including remdesivir
68 and GS-441524 have recently been successfully used to treat cats with FIP²⁷.

69 FCoV and CCoV both belong to the *Alphacoronavirus 1* species alongside the porcine transmissible
70 gastroenteritis virus (TGEV) and, probably, the never fully sequenced rabbit enteric
71 coronavirus^{28,29}. Both FCoV and CCoV have evolved two different serotypes through complex
72 recombination events between the two viruses with a suspected gradual evolution from CCoV-II
73 to TGEV and the later spike deletion to porcine respiratory coronavirus (PRCV)^{23,30}. Whilst
74 recombination events between CCoV and FCoV have significantly contributed to the serotype
75 evolution and have been frequently described, so far, none of them lead to enhanced
76 transmissibility of FIP beyond closest contact^{10,23,31,32}. Similarly, recombination events have been
77 reported between CCoV and TGEV³³, the latter has been found to recombine with the
78 pedacoronavirus (alphacoronavirus genus) porcine epidemic diarrhoea virus⁶. These
79 observations are particularly important in view of the *Alphacoronavirus 1*-related human
80 infections recently observed^{19,22}.

81 Earlier this year, we alerted the veterinary field to an outbreak of FIP in Cyprus, where there had
82 been a concerning increase in cases¹¹. Cases were recorded as FIP only if they had compatible
83 clinicopathological signs and a positive RT-qPCR for FCoV in one of the following samples;
84 peritoneal fluid, pleural fluid, cerebrospinal fluid, fine needle aspiration biopsies, or tissue
85 biopsies from granulomatous lesions. In comparison, in 2021 and 2022, there were three and four
86 RT-qPCR confirmed FIP cases recorded in Cyprus, respectively, to date in 2023 (January-August),
87 165 cases have been confirmed. This represents more than a 40-fold increase. The outbreak
88 emerged in January 2023 in Nicosia, the capital of Cyprus. An increase in cases was first observed
89 in January 2023 and by February Nicosia recorded the peak number of cases in any district
90 (Figure 1A & B). The next highest number of cases was observed in Famagousta, which peaked in
91 March, and by then the outbreak had spread to all districts of the Republic of Cyprus.
92 (Supplementary Tables 1-5). In June and July there was a decline in RT-qPCR confirmed cases,
93 which coincided with a large media awareness campaign to alert veterinarians to the spread of
94 FIP¹¹. This fall in RT-qPCR confirmed cases is likely due to most veterinarians diagnosing cases
95 based on clinicopathological findings without performing PCR testing due to the additional
96 financial cost. On August 3rd, the Republic of Cyprus minister's cabinet approved the use of the
97 stocked human coronavirus medications to be used for cats with FIP. In order for veterinarians
98 to have access to this medication, amongst others, a PCR confirmation was required, reflecting
99 the increased cases seen during August 2023. In order for veterinarians to have access to this

100 medication a PCR confirmation was required, reflecting the increased cases seen during August
 101 2023 (Figure 1A & B). The number of unreported cases in Cyprus is very high, not least due to the
 102 high number of feral cats. Estimates from the Pancyprian Veterinary Association indicate around
 103 8,000 deaths due to FIP up to mid-July 2023. Furthermore, in October 2023, a first imported case
 104 of FIP was confirmed in the UK.



105

106 **Figure 1: Epidemiology and Pathology of the FIP outbreak in Cyprus, 2023.** **A)** Distribution of RT-PCR confirmed positive FIP
 107 cases across Cyprus. First image locates Cyprus within the Eastern Mediterranean. Darker colors indicate higher numbers of confirmed
 108 cases over time within each district. **B)** RT-PCR confirmed case rates resolved by time and province. **C)** Clinical presentation of cats
 109 with FIP due to FCoV-23. Left; cat with the effusive form of FIP showing abdominal distention due to peritoneal effusion, an unkempt
 110 coat, low body condition score, and poor muscle condition. Right; cat presenting with jaundice evidenced by yellow/orange
 111 discoloration of the mucous membranes and mucocutaneous junctions. Images courtesy of Eva Georgiadi. **D)** Photomicrograph of
 112 fluid smear from a peritoneal effusion from a cat with confirmed FIP due to FCoV-23 infection. Non-degenerative neutrophils are
 113 present on a protein rich background shown using a Modified Wright's stain. Scale bar represents 20µm. **E)** Photomicrographs
 114 showing a section of colonic mucosa and submucosa from a cat with confirmed FIP due to FCoV-23 infection. Top; H&E-stained
 115 histology section shows coalescing infiltration of predominantly the submucosa by aggregates of primarily neutrophils and
 116 macrophages surrounded by fewer lymphocytes and plasma cells. The muscularis mucosae is disrupted by the inflammation. Bottom;
 117 Immunohistochemistry staining against FCoV in a histology section mirroring the above. Extensive positive FCoV cytoplasmic staining
 118 for cells at the center of each aggregate/pyogranuloma in cells with macrophage-like morphology. Scale bar represents 200µm.

119 The most common clinical form of FIP was effusive (69.7%; Figure 1C), followed by neurological
 120 FIP (27.9%) and the non-effusive form (2.4%) (Supplementary table 4). Where peritoneal fluid
 121 was assessed by cytology, non-degenerative neutrophils admixed with macrophages and small
 122 lymphocytes were seen in a protein rich background (Figure 1D). Five cases were assessed by
 123 histopathology, including intestinal mass (n=1), lymph node (n=2), and kidney (n=2). All showed


124 similar histological features, with multifocal to coalescing, pyogranulomatous to necrotising and
125 lymphoplasmacytic inflammation (Figure 1E). The angiocentric nature can be seen in some areas,
126 whilst in others there is total effacement of the tissue. Immunohistology for FCoV antigen
127 demonstrated a heavy viral load within intralesional macrophages (Figure 1E).

128 RNA samples were obtained from 91 confirmed FIP cases between 2021 and 2023, representing
129 a mixture of geographic origin, sex, and clinical presentation (Supplementary Tables 6-11). They
130 were sequenced using cDNA/PCR-amplification-based Nanopore sequencing to better
131 understand the outbreak and to determine if cat-to-cat transmission of FIPV is occurring.
132 Additional samples were submitted from two cats presenting with FIP following recent import
133 from Cyprus to the UK. Initial focus laid on amplification of the spike, which was successful in 43
134 of the Cypriot samples and in the two imported UK cat samples. The other samples were degraded
135 or contained too few viral copies. None of the seven samples from before 2023 amplified
136 (Supplementary Tables 12-17). Other regions of the genome were amplified in several
137 individuals; however, none of the cats had the entire genome amplified due to intentional
138 conservation of limited samples until a working primer scheme is designed for the entire genome.

139 The sequenced spike region of the FCoV samples produced three distinct versions of the spike
140 sequence. BLAST was used to identify close relatives of these spike sequences. The first is a spike
141 sequence most closely related to an FCoV (genbank ID MT444152.1) with 79% similarity, which
142 occurred in one Cypriot and one UK-import sample, and the other two are almost entirely CCoV
143 spike sequence, flanked by FCoV sequence. The CCoV sequence is most closely related to the
144 NA/09 strain (GB JF682842), a hypervirulent pantropic canine coronavirus (pCCoV)³⁴, at 97%
145 sequence identity. The spike sequence is also closely related to other pCCoV spike sequences with
146 only partial spike sequences available (Figure 2, Supplementary Figure 1). Two of the samples,
147 one Cypriot and one UK-import case, showed high similarity with FIPV-1 spikes. However, all
148 other samples, including one UK-import case align with a pCCoV spike. This is likely a defining
149 feature of the virus circulating in the outbreak in Cyprus. There are two versions of this spike
150 gene, one of which has a deletion of approximately 630bp near the beginning of the spike
151 sequence in the N terminal domain, and this deletion version is present in the majority, 35/43 of
152 the pCCoV spikes sequenced.


153 Regions of POL1ab and ORF3c/E/M were amplified in several of the cats in addition to the spike
154 genes. These sequences and the spike sequences were individually aligned to the CCoV, FCoV
155 and FCoV whole genome sequences available on NCBI. Figure 2 shows maximum likelihood
156 trees all three different regions (also Supplementary Figures 2-4). While the POL1ab and
157 ORF3c/E/M amplicons all cluster with FCoV, the spike sequences cluster with CCoV, most

158 closely with the pantropic strains NA/09 and CB/05. The spike amplicon from one UK-import cat
159 clusters among the spike sequences from the outbreak in Cyprus.



161
162
163
164
165
166
167

Figure 2: Genomic sequence analysis of Cypriot/UK-import FCoV cases. Sequences from three different genomic regions: Orf1b, spike, and Orf3c/E/M, as indicated by the regions marked on the overview of the genome, were obtained through Nanopore sequencing from 22, 45, and 22, Cypriot and UK-import samples, respectively. Following initial BLAST analysis, maximum likelihood trees were generated including other FCoV and CCoV strains to assess genetic similarity of each region. CCoV VII genomes are highlighted in light blue with pCCoVII genomes within this region displayed in a darker blue. FCoV I genomes are highlighted in pink and FCoV II genomes in orange. Samples from Cyprus (Yellow) and one UK-imported Cypriot cat (Green) can be seen clustered with FCoV I sequences in the Orf1b and Orf3c/E/M regions. The spike gene, however, clusters with CCoV VII, most closely with pCCoVII. Different numbers of sequences are present in each tree due to missing sequence or poor sequence quality and/or alignments in genomes downloaded from NCBI, and due to not all regions being sequenced in all individuals from our samples. The figure was created with Biorender.



168

169

170

171

172

173

174

175

176

177

178

179

180

Figure 3: Recombination analysis. **A)** Visualizations of a recombination analysis carried out on the assembled FCoV-23 genome and representative genomes of FCoV (green), FCoVII (yellow) and pCCoV (purple). An annotated sequence can be found in Supplementary File 1 and will be deposited to Genbank prior to publication. The blue panel shows the gap in the assembled genome, and the grey panel shows the likely recombination break region, with an orange vertical line showing the likely break point. The first panel shows the results of the Bootscan analysis, the second panel shows the sequence distance, and the third panel shows the RDP pairwise identity analysis. All three panels show good support for the recombination between FCoV and pCCoV. These results are further supported by high statistical likelihood of recombination shown in Supplementary Table 19. **B)** Schematic representation of major recombinations observed in FCoV and CCoV. A common ancestral origin virus is thought to have given rise to the original FCoV and CCoV types with further evolution in CCoVs yielding CCoVII and CCoV/II serotypes. FCoVs are thought to have recombined with CCoVII to form FCoVII. FCoVII/CCoVII recombinations have shown to have different recombination points as highlighted by the different colorations (reviewed in ²³). The Cypriot FCoV strain, termed FCoV-23, is a recombinant between an FCoV strain and a spike recombination with a pantropic CCoV, pCCoV. Furthermore, a deletion variant is observed in a majority of sequenced cases (white box).


181 A representative genome of FCoV-23 was assembled from amplicons amplified from multiple
182 Cypriot samples (Supplementary File 1), a single gap of 1,221bp remains in this assembly at the
183 second recombination breakpoint. Supplementary Figure 5 shows a neighbour joining tree for
184 the assembled coronavirus along with other members of *Alphacoronavirus 1* and a distantly
185 related Canine Respiratory Coronavirus as an outgroup. The assembled genome clusters with
186 representatives of FCoV, similar to the clustering of the amplicons outside of the spike region.

187 A recombination analysis was carried out comparing the FCoV-23 genome with FCoV, FCoV and
188 CCoV strain CB/05, since NA/09 is not available as a complete genome. Figure 3A shows
189 visualisations of the Bootscan³⁵ analysis, the RDP5³⁶ analysis and the pairwise distances between
190 the sequences. Significant p-values supporting the recombination were reported by multiple
191 methods as listed in Supplementary Table 19. The MaxChi³⁷ breakpoint matrix is available in
192 Supplementary Figure 6. Despite the second breakpoint being missing from the analysis due to
193 the remaining gap in the genome, the recombination is very clear and includes a small region of
194 the POL1b gene and the majority of the spike gene, but none of the genes to the 3' end of spike.
195 Some reads, while not sufficiently high coverage to create a consensus for this gap region, suggest
196 that the recombination break point occurs within the spike gene, close to the 3' end
197 (Supplementary Figure 7). Figure 3B shows the historical break point between FCoV and CCoV
198 that created FCoV alongside the recombination identified here.

199 The main determinant in disease development and transmission of FCoV-23 appears to be the
200 spike recombination. One of the main suggested determinants of biotype changes, the furin
201 cleavage site (FCS) at the S1/S2 interface^{23,26} is absent in FCOVs and also FCoV-23. An interesting
202 observation, however, is that the majority of samples show a deletion in domain 0, strongly
203 resembling the deletion observed in TGEV and porcine respiratory coronavirus (PRCV) (Figure
204 4A). In other coronaviruses, including TGEV³⁸ and CCoV-HuPn-2018³⁹, domain 0 was shown to
205 bind sialosides. Modelling the structure of spike against the closely related, experimentally
206 confirmed CCoV-HuPn-2018 spike³⁹ shows a much more compact confirmation for the domain 0
207 deletion spike and similarity to a structural prediction based on a “swung-out” or a “proximal”
208 confirmation template (Figure 4B, Supplementary Figure 8). A number of amino acid changes
209 were observed between “classical” FECV-2 and FIPV-2 spikes. In particular domains A and B, the
210 receptor binding domain (RBD) show a number of class changing amino acid changes distinct
211 from FCoV-2 spikes (Figure 4A). Modelling the RBD changes against the structure highlights
212 changes at positions 546 and 595, as well as 556, 603, and 636 as being potentially strongly
213 influential to receptor binding properties (Figure 4C).

214 Previously indicated key proteins for biotype switch spike, Orf3abc and 7b were compared to the
215 recently published computational analysis of mutations observed in FECV versus FIPV by Zehr *et*

216 *al.*²⁶. Unfortunately, the suggested key determinant of FIPV in the FCoV-2 spike, position 1404, is
 217 not yet resolved in FCoV-23. Other positions in spike show new mutations or are suggestive of
 218 FIPV (Supplementary Table 20). Whilst a new mutation each was identified in Orf3a and b, no
 219 specific indications of pathogenesis could be determined (Supplementary Table 21). Similarly, in
 220 Orf7b, two new mutations but no indication of pathogenesis could be identified (Supplementary
 221 Table 22).



222 **Figure 4: Protein sequence and structural analysis of FCoV-23 Spike.** **A)** Analysis of the different domains of FCoV-23 spike.
 223 Sequencing depth in the regions highlighted with a dashed border are not sufficient to call individual bases with enough certainty to
 224 perform sequence analysis. Therefore, these regions have been excluded here. Domain 0 in its full-length version shows high similarity
 225 to CB/05 pCCoV; however most prominent is the large deletion from aa51-264 strongly resembling the deletion previously observed
 226 between the TGEV and PRCV spike. Multi-sequence alignment was performed against four confirmed FECV-2 and four confirmed
 227 FIPV-2 mirroring sequences used for computational analysis by Zehr *et al.*²⁶. Highlighted are amino acid changes with significant
 228 change against FCoVIIs and also position 546, where a Leucin is more predominant in FIPV rather than FECV sequences. Colors are
 229 following the RasMol amino acid color scheme. **B)** Structural modelling of the “full-length” or long spike version, represented by
 230 sample G8, and the “domain 0 deletion” or short version, represented by sample C10. Samples were modelled against the CCov-HuPN-
 231 2018, experimentally determined spike in the swung out confirmation 7usa.1.A³⁹. The proximal confirmation and comparisons may
 232 be found in Supplementary Figure 8. Colors indicate confidence with blue highlighting strong and red highlighting weak confidence.
 233 **C)** Modelling or amino acid changes on a structural prediction of the FCoV-23 RBD against CCov-HuPN-2018 7u8l.1.B. Significant
 234 amino acid changes as identified in A) are highlighted with side-chains in blue for variations to FCoVIIs distant from the RBD, red for
 235 variations close to the RBD, orange for the variation at aa546 similar to FIPV-2, and olive for the variation differing both from FCoVII
 236 and pCCoV. A comparison showing a confidence model of the FCoV-23 RBD structure prediction paired with the CCov-HuPN-2018-
 237 canine aminopeptidase N (APN) is shown for orientation and binding visualization in the top right corner. Colors indicate confidence
 238 with blue highlighting strong and red highlighting weak confidence.
 239

240 Discussion

241 Recombination within the *Alphacoronavirus 1* species has been frequently observed previously
242 and has even given rise to the FCoV serotype^{5,23,24}(Figure 3B) in cats. Even complex
243 recombination between FCoV and CCoV has previously been observed¹⁰. However, in this work,
244 we have identified a new subtype of FCoV that has recombined with a hypervirulent strain of
245 pCCoV. The recombinant, which we propose naming FCoV-23, shows clearly distinct properties
246 from previously observed FCoV infections. The sequence similarity found between FCoV-23 and
247 CCoV is higher than would be expected without an additional, recent recombination event.

248 Preliminary data suggest there may be no need for a biotype change to result in FIP and there is
249 compelling evidence supportive of direct transmission of FCoV-23. However, more work is
250 needed, including investigation into asymptomatic carriers. Of support, onset of FIP appears
251 rapid and shows little discrimination in age of the infected cats. Most importantly, remarkably
252 high sequence identity from isolates collected at different times and locations, is highly
253 supportive of direct transmission of FCoV-23. The scale of this FIP outbreak has not been
254 observed previously. Concerningly, Cyprus has a high population of unowned cats that are
255 frequently relocated to other parts of Europe, and the wider world. The risk of spreading this
256 outbreak is significant as evidenced by the first confirmed UK case⁴⁰. This is exemplified by the
257 recent confirmation of a first UK-imported case with further investigations into other cases
258 ongoing.

259 CCoV infections in dogs are typically self-limiting, producing mild or asymptomatic enteritis.
260 Previous work on the FCoV-23 close relative strain, CCoV NA/09 and CB/05, found the virus was
261 hypervirulent and infected a range of organs in canine hosts. CCoV typically infects cells of the
262 enteric tract, but pCCoVs were shown to spread to a range of internal organs, including intestine,
263 lung, spleen, liver, kidney, lymph nodes, brain, and even T and B cells^{34,41-43}. CB/05 has also been
264 identified as responsible for small outbreaks⁴¹.

265 The clinical signs of FCoV-23 are similar to those observed in classical FIP cases. However, FIP
266 infection itself already shows a strong pantropism, affecting many organs in infected cats²⁵. What
267 is remarkable, is the high number of FCoV-23 positive cells observed in immunohistochemistry
268 samples (Figure 1C). This is indicative of high viral loads, but must be validated through
269 quantification. Furthermore, a relatively high percent (Supplementary Table 4) of confirmed
270 cases in Cyprus was presented with neurological signs (28%), which is double of what would be
271 expected with classical FIP (14%)²⁷. This may be due to increased awareness of presentation or
272 be inherent to FCoV-23 neurotropism; however, further investigation is required.

273 Significant changes to the spike protein in FCoV-23 may provide some clues as to the enhanced
274 pathogenicity of this virus. FCoV-23, like other FCoVs and CCoV, does not contain an FCS at the

275 S1/S2, and the related virus CCoV-HuPn-2018 was experimentally found to be uncleaved³⁹.
276 Uncleaved spike has been shown to be more stable than cleaved one and could enhance faecal
277 shedding and stability in the environment⁴⁴. Conversely, the cleavage at S1/S2 may facilitate the
278 movement of the N-terminal domains and allow the RBD to adopt the receptor-binding-
279 competent form. However, the deletion of the N-terminal domain 0 may compensate for the
280 increased rigidity. Whilst a similar deletion between TGEV and PRCV was initially indicated as
281 the determinant between a primarily enteric and primarily respiratory tropism, respectively^{45,46},
282 a recent study shows a different result *in vivo*⁴⁷. Sialoside binding is an important feature of
283 coronavirus infections and may contribute to intracellular spread⁴⁸. It is then all the more
284 surprising that FCoV-23 loses the sialoside-binding domain 0. However, whilst binding to
285 sialosides can enhance virus attachment and entry into host cells, binding to sugars can lead to
286 increased retention of virus on producer cells. Whilst some viruses, like influenza, solve this issue
287 by encoding their own sugar-cleaving enzyme, neuraminidase, coronaviruses must find a balance
288 through modifying glycoprotein binding⁴⁹. Losing domain 0 could therefore be a trade-off to
289 enhance virus release. This may be compensated by the earlier discussed enhanced flexibility of
290 spike and increased binding efficiency at the RBD through mutation. These are manifold in the
291 FCoV-23 pCCoV recombinant and in particular mutations at position 546 (already possibly
292 associated with FIP) and 595 are likely to have a strong impact on aminopeptidase N receptor
293 binding (Figure 4C).

294 Recombination between FCoVI and pCCoVs is not surprising in that i) such recombinations have
295 been observed before, and ii) pCCoVs have evolved in Greece and south eastern Europe^{34,42}.
296 However, the emergence of pCCoV in Greece happened over 18 years ago, so the question as to
297 why this happened now is unclear yet. One possible explanation is the “right mutation, right time,
298 right place” theory. Recombination between feline and canine coronaviruses happen frequently
299 but as previous reports show, they rarely spread. Introduction of a more successful, spreading
300 variant to a dense population, like the cats in Cyprus, may be sufficient to allow this virus to cause
301 an outbreak. Whilst alphacoronaviruses show great cross-neutralizing activity³⁹, neutralising
302 immune evasion of FCoV-23 may be a contributing factor as indicated by the infection of cats of
303 all age groups. However, further investigation is required to determine shedding routes and
304 virulence. Preliminary RT-qPCR results and high virus-infected cell positivity in the colon are
305 strongly indicative of faecal shedding (data not shown and figure 1D). Analysis of historic
306 samples, (asymptomatic) cats and dogs may help further evaluate the origins of this virus.

307 This paper reports the emergence of a new *alphacoronavirus 1* feline/canine coronavirus that
308 shows high spreading potential with the associated pathology of lethal FIP if left untreated.
309 Further investigations into the properties of this new virus are now essential. Whilst antivirals,

310 including GS-441524 and molnupiravir were successfully used to treat some cats affected by
311 FCoV-23, early treatment is essential but associated costs are often prohibitive. Prevention of
312 spread and the development of new vaccines are important to stop this virus epizootic from
313 becoming a panzootic.

314 **Acknowledgements**

315 The authors like to thank the Pancyprian Veterinary Association and all the veterinarians in
316 Cyprus for sample submission. We would like to thank Dr Sam Lycett, The Roslin Institute, The
317 University of Edinburgh for advice on sequence analysis.

318

319 **Author contributions**

320 Conceptualization, C.A., A.W., D.G-M., S. M. and C.T-B.; Methodology, C.A., A.W., S.M., and C.T-B. ;
321 Validation, C.A., A.W., S.M. and C.T-B.; Formal Analysis, A.W., S.M. and C.T-B.; Investigation, C.A.,
322 A.W., D.E., M.O., S.F. , A.M., M.L., R.H., C.T-B.; Resources, C.A., A.W., D.E., M.L., A.H., A.Z., S.L., M.G. and
323 C.T-B.; Data Curation, A.W., S.M., and C. T-B.; Writing – Original Draft Preparation, C.A., A.W., and
324 C.T.B.; Writing – Review & Editing, C.A., A.W., S.F., D.G-M., S.M. and C.T-B.; Visualization, A.W., S.M.
325 and C.T-B.; Supervision, C.A. and C.T-B.; Project Administration, C.A. and C.T-B.; Funding
326 Acquisition, C.A., and C.T-B.

327

328 **Funding**

329 This work was supported by EveryCat Health Foundation award number EC23-OC1 (C.A., D.G-M.,
330 C.T-B.), Vet Dia Gnosis Ltd (C.A.). This research was funded by the BBSRC Institute Strategic
331 Programme grant funding to the Roslin Institute, grant numbers BBS/E/D/20241866,
332 BBS/E/D/20002172, and BBS/E/D/20002174 (C.T-B.).

333

334 **Competing interests**

335 The authors declare no competing interests.

336 References

- 337 1 Olival, K. J. *et al.* Host and viral traits predict zoonotic spillover from mammals. *Nature* **546**,
338 646-650, doi:10.1038/nature22975 (2017).
- 339 2 Zhou, P. *et al.* Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus
340 of bat origin. *Nature* **556**, 255-258, doi:10.1038/s41586-018-0010-9 (2018).
- 341 3 Nova, N. Cross-Species Transmission of Coronaviruses in Humans and Domestic Mammals,
342 What Are the Ecological Mechanisms Driving Transmission, Spillover, and Disease Emergence?
343 *Front Public Health* **9**, 717941, doi:10.3389/fpubh.2021.717941 (2021).
- 344 4 Muller, N. F., Kistler, K. E. & Bedford, T. A Bayesian approach to infer recombination patterns
345 in coronaviruses. *Nat Commun* **13**, 4186, doi:10.1038/s41467-022-31749-8 (2022).
- 346 5 Herrewegh, A. A., Smeenk, I., Horzinek, M. C., Rottier, P. J. & de Groot, R. J. Feline coronavirus
347 type II strains 79-1683 and 79-1146 originate from a double recombination between feline
348 coronavirus type I and canine coronavirus. *Journal of virology* **72**, 4508-4514,
349 doi:10.1128/JVI.72.5.4508-4514.1998 (1998).
- 350 6 Boniotti, M. B. *et al.* Porcine Epidemic Diarrhea Virus and Discovery of a Recombinant Swine
351 Enteric Coronavirus, Italy. *Emerging infectious diseases* **22**, 83-87,
352 doi:10.3201/eid2201.150544 (2016).
- 353 7 Pedersen, N. C., Ward, J. & Mengeling, W. L. Antigenic relationship of the feline infectious
354 peritonitis virus to coronaviruses of other species. *Archives of virology* **58**, 45-53,
355 doi:10.1007/BF01315534 (1978).
- 356 8 Pedersen, N. C. A review of feline infectious peritonitis virus infection: 1963-2008. *Journal of*
357 *feline medicine and surgery* **11**, 225-258, doi:10.1016/j.jfms.2008.09.008 (2009).
- 358 9 Kannekens-Jager, M. M. *et al.* SARS-CoV-2 infection in dogs and cats is associated with contact
359 to COVID-19-positive household members. *Transbound Emerg Dis* **69**, 4034-4040,
360 doi:10.1111/tbed.14713 (2022).
- 361 10 Terada, Y. *et al.* Emergence of pathogenic coronaviruses in cats by homologous recombination
362 between feline and canine coronaviruses. *PLoS One* **9**, e106534,
363 doi:10.1371/journal.pone.0106534 (2014).
- 364 11 Attipa, C. *et al.* Concerning feline infectious peritonitis outbreak in Cyprus. *Vet Rec* **192**, 449-
365 450, doi:10.1002/vetr.3143 (2023).
- 366 12 Jaimes, J. A. & Whittaker, G. R. Feline coronavirus: Insights into viral pathogenesis based on
367 the spike protein structure and function. *Virology* **517**, 108-121,
368 doi:10.1016/j.virol.2017.12.027 (2018).
- 369 13 Amer, H. M. Bovine-like coronaviruses in domestic and wild ruminants. *Anim Health Res Rev*
370 **19**, 113-124, doi:10.1017/S1466252318000117 (2018).
- 371 14 Woo, P. C., Lau, S. K., Huang, Y. & Yuen, K. Y. Coronavirus diversity, phylogeny and interspecies
372 jumping. *Exp Biol Med (Maywood)* **234**, 1117-1127, doi:10.3181/0903-MR-94 (2009).
- 373 15 Small, J. D. & Woods, R. D. Relatedness of rabbit coronavirus to other coronaviruses. *Adv Exp*
374 *Med Biol* **218**, 521-527, doi:10.1007/978-1-4684-1280-2_68 (1987).
- 375 16 Gao, Y. Y. *et al.* An updated review of feline coronavirus: mind the two biotypes. *Virus Res* **326**,
376 199059, doi:10.1016/j.virusres.2023.199059 (2023).
- 377 17 Haake, C., Cook, S., Pusterla, N. & Murphy, B. Coronavirus Infections in Companion Animals:
378 Virology, Epidemiology, Clinical and Pathologic Features. *Viruses* **12**, doi:10.3390/v12091023
379 (2020).
- 380 18 Pedersen, N. C. An update on feline infectious peritonitis: virology and immunopathogenesis.
381 *Vet J* **201**, 123-132, doi:10.1016/j.tvjl.2014.04.017 (2014).
- 382 19 Vlasova, A. N. *et al.* Animal alphacoronaviruses found in human patients with acute respiratory
383 illness in different countries. *Emerg Microbes Infect* **11**, 699-702,
384 doi:10.1080/22221751.2022.2040341 (2022).
- 385 20 Saif, L. J. Animal coronaviruses: what can they teach us about the severe acute respiratory
386 syndrome? *Rev Sci Tech* **23**, 643-660, doi:10.20506/rst.23.2.1513 (2004).

- 387 21 Wang, Q., Vlasova, A. N., Kenney, S. P. & Saif, L. J. Emerging and re-emerging coronaviruses in
388 pigs. *Curr Opin Virol* **34**, 39-49, doi:10.1016/j.coviro.2018.12.001 (2019).
- 389 22 Corman, V. M., Muth, D., Niemeyer, D. & Drosten, C. Hosts and Sources of Endemic Human
390 Coronaviruses. *Adv Virus Res* **100**, 163-188, doi:10.1016/bs.aivir.2018.01.001 (2018).
- 391 23 Jaimes, J. A., Millet, J. K., Stout, A. E., Andre, N. M. & Whittaker, G. R. A Tale of Two Viruses:
392 The Distinct Spike Glycoproteins of Feline Coronaviruses. *Viruses* **12**, doi:10.3390/v12010083
393 (2020).
- 394 24 Le Poder, S. Feline and canine coronaviruses: common genetic and pathobiological features.
395 *Advances in virology* **2011**, 609465, doi:10.1155/2011/609465 (2011).
- 396 25 Tasker, S. *et al.* Feline Infectious Peritonitis: European Advisory Board on Cat Diseases
397 Guidelines. *Viruses* **15**, doi:10.3390/v15091847 (2023).
- 398 26 Zehr, J. D. *et al.* Natural selection differences detected in key protein domains between non-
399 pathogenic and pathogenic feline coronavirus phenotypes. *Virus Evol* **9**, vead019,
400 doi:10.1093/ve/vead019 (2023).
- 401 27 Taylor, S. S. *et al.* Retrospective study and outcome of 307 cats with feline infectious
402 peritonitis treated with legally sourced veterinary compounded preparations of remdesivir
403 and GS-441524 (2020-2022). *Journal of feline medicine and surgery* **25**, 1098612X231194460,
404 doi:10.1177/1098612X231194460 (2023).
- 405 28 Descoteaux, J. P. *et al.* An enteric coronavirus of the rabbit: detection by immunoelectron
406 microscopy and identification of structural polypeptides. *Archives of virology* **84**, 241-250,
407 doi:10.1007/BF01378976 (1985).
- 408 29 Lefkowitz, E. J. *et al.* Virus taxonomy: the database of the International Committee on
409 Taxonomy of Viruses (ICTV). *Nucleic Acids Res* **46**, D708-D717, doi:10.1093/nar/gkx932 (2018).
- 410 30 Whittaker, G. R., Andre, N. M. & Millet, J. K. Improving Virus Taxonomy by Recontextualizing
411 Sequence-Based Classification with Biologically Relevant Data: the Case of the
412 Alphacoronavirus 1 Species. *mSphere* **3**, doi:10.1128/mSphereDirect.00463-17 (2018).
- 413 31 Wang, Y. T., Su, B. L., Hsieh, L. E. & Chueh, L. L. An outbreak of feline infectious peritonitis in a
414 Taiwanese shelter: epidemiologic and molecular evidence for horizontal transmission of a
415 novel type II feline coronavirus. *Vet Res* **44**, 57, doi:10.1186/1297-9716-44-57 (2013).
- 416 32 Chang, H. W., de Groot, R. J., Egberink, H. F. & Rottier, P. J. Feline infectious peritonitis: insights
417 into feline coronavirus pathobiogenesis and epidemiology based on genetic analysis of the
418 viral 3c gene. *J Gen Virol* **91**, 415-420, doi:10.1099/vir.0.016485-0 (2010).
- 419 33 Decaro, N. *et al.* Recombinant canine coronaviruses related to transmissible gastroenteritis
420 virus of Swine are circulating in dogs. *Journal of virology* **83**, 1532-1537,
421 doi:10.1128/JVI.01937-08 (2009).
- 422 34 Ntafis, V. *et al.* Molecular characterization of a canine coronavirus NA/09 strain detected in a
423 dog's organs. *Archives of virology* **157**, 171-175, doi:10.1007/s00705-011-1141-6 (2012).
- 424 35 Martin, D. P., Posada, D., Crandall, K. A. & Williamson, C. A modified bootscan algorithm for
425 automated identification of recombinant sequences and recombination breakpoints. *AIDS Res*
426 *Hum Retroviruses* **21**, 98-102, doi:10.1089/aid.2005.21.98 (2005).
- 427 36 Martin, D. P. *et al.* RDP5: a computer program for analyzing recombination in, and removing
428 signals of recombination from, nucleotide sequence datasets. *Virus Evolution* **7**,
429 doi:10.1093/ve/veaa087 (2020).
- 430 37 Smith, J. M. Analyzing the mosaic structure of genes. *J Mol Evol* **34**, 126-129,
431 doi:10.1007/bf00182389 (1992).
- 432 38 Schultze, B. *et al.* Transmissible gastroenteritis coronavirus, but not the related porcine
433 respiratory coronavirus, has a sialic acid (N-glycolylneuraminic acid) binding activity. *Journal*
434 *of virology* **70**, 5634-5637, doi:10.1128/JVI.70.8.5634-5637.1996 (1996).
- 435 39 Tortorici, M. A. *et al.* Structure, receptor recognition, and antigenicity of the human
436 coronavirus CCoV-HuPn-2018 spike glycoprotein. *Cell* **185**, 2279-2291 e2217,
437 doi:10.1016/j.cell.2022.05.019 (2022).

- 438 40 Maggi, R. G. *et al.* Vector-borne and other pathogens of potential relevance disseminated by
439 relocated cats. *Parasit Vectors* **15**, 415, doi:10.1186/s13071-022-05553-8 (2022).
- 440 41 Buonavoglia, C. *et al.* Canine coronavirus highly pathogenic for dogs. *Emerging infectious*
441 *diseases* **12**, 492-494, doi:10.3201/eid1203.050839 (2006).
- 442 42 Decaro, N. *et al.* Molecular characterisation of the virulent canine coronavirus CB/05 strain.
443 *Virus Res* **125**, 54-60, doi:10.1016/j.virusres.2006.12.006 (2007).
- 444 43 Marinaro, M. *et al.* Prolonged depletion of circulating CD4+ T lymphocytes and acute
445 monocytosis after pantropic canine coronavirus infection in dogs. *Virus Res* **152**, 73-78,
446 doi:10.1016/j.virusres.2010.06.006 (2010).
- 447 44 Wrobel, A. G. *et al.* SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus
448 evolution and furin-cleavage effects. *Nat Struct Mol Biol* **27**, 763-767, doi:10.1038/s41594-
449 020-0468-7 (2020).
- 450 45 Sanchez, C. M. *et al.* Targeted recombination demonstrates that the spike gene of
451 transmissible gastroenteritis coronavirus is a determinant of its enteric tropism and virulence.
452 *Journal of virology* **73**, 7607-7618, doi:10.1128/JVI.73.9.7607-7618.1999 (1999).
- 453 46 Sanchez, C. M., Pascual-Iglesias, A., Sola, I., Zuniga, S. & Enjuanes, L. Minimum Determinants
454 of Transmissible Gastroenteritis Virus Enteric Tropism Are Located in the N-Terminus of Spike
455 Protein. *Pathogens* **9**, doi:10.3390/pathogens9010002 (2019).
- 456 47 Wang, G. *et al.* The N-Terminal Domain of Spike Protein Is Not the Enteric Tropism
457 Determinant for Transmissible Gastroenteritis Virus in Piglets. *Viruses* **11**,
458 doi:10.3390/v11040313 (2019).
- 459 48 Qing, E., Hantak, M., Perlman, S. & Gallagher, T. Distinct Roles for Sialoside and Protein
460 Receptors in Coronavirus Infection. *mBio* **11**, doi:10.1128/mBio.02764-19 (2020).
- 461 49 Buchanan, C. J. *et al.* Pathogen-sugar interactions revealed by universal saturation transfer
462 analysis. *Science* **377**, eabm3125, doi:10.1126/science.abm3125 (2022).
- 463 50 Gut, M., Leutenegger, C. M., Huder, J. B., Pedersen, N. C. & Lutz, H. One-tube fluorogenic
464 reverse transcription-polymerase chain reaction for the quantitation of feline coronaviruses.
465 *J Virol Methods* **77**, 37-46, doi:10.1016/s0166-0934(98)00129-3 (1999).
- 466 51 Quick, J. *et al.* Multiplex PCR method for MinION and Illumina sequencing of Zika and other
467 virus genomes directly from clinical samples. *Nature Protocols* **12**, 1261-1276,
468 doi:10.1038/nprot.2017.066 (2017).
- 469 52 Sayers, E. W. *et al.* Database resources of the national center for biotechnology information.
470 *Nucleic Acids Res* **50**, D20-d26, doi:10.1093/nar/gkab1112 (2022).
- 471 53 Vierstraete, A. R. & Braeckman, B. P. Amplicon_sorter: A tool for reference-free amplicon
472 sorting based on sequence similarity and for building consensus sequences. *Ecol Evol* **12**,
473 e8603, doi:10.1002/ece3.8603 (2022).
- 474 54 Li, H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics* **34**, 3094-3100,
475 doi:10.1093/bioinformatics/bty191 (2018).
- 476 55 Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search
477 tool. *J Mol Biol* **215**, 403-410, doi:10.1016/s0022-2836(05)80360-2 (1990).
- 478 56 Robinson, J. T. *et al.* Integrative genomics viewer. *Nature Biotechnology* **29**, 24-26,
479 doi:10.1038/nbt.1754 (2011).
- 480 57 Amanda, W. *et al.* No part gets left behind: Tiled nanopore sequencing of whole ASFV
481 genomes stitched together using Lilo. *bioRxiv*, 2021.2012.2001.470769,
482 doi:10.1101/2021.12.01.470769 (2021).
- 483 58 Katoh, K., Misawa, K., Kuma, K. i. & Miyata, T. MAFFT: a novel method for rapid multiple
484 sequence alignment based on fast Fourier transform. *Nucleic Acids Research* **30**, 3059-3066,
485 doi:10.1093/nar/gkf436 (2002).
- 486 59 Kumar, S., Stecher, G. & Tamura, K. MEGA7: Molecular Evolutionary Genetics Analysis Version
487 7.0 for Bigger Datasets. *Mol Biol Evol* **33**, 1870-1874, doi:10.1093/molbev/msw054 (2016).

- 488 60 Nguyen, L. T., Schmidt, H. A., von Haeseler, A. & Minh, B. Q. IQ-TREE: a fast and effective
489 stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol Biol Evol* **32**, 268-
490 274, doi:10.1093/molbev/msu300 (2015).
- 491 61 Rambaut, A., Lam, T. T., Max Carvalho, L. & Pybus, O. G. Exploring the temporal structure of
492 heterochronous sequences using TempEst (formerly Path-O-Gen). *Virus Evolution* **2**,
493 doi:10.1093/ve/vew007 (2016).
- 494 62 Letunic, I. & Bork, P. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree
495 display and annotation. *Nucleic Acids Research* **49**, W293-W296, doi:10.1093/nar/gkab301
496 (2021).
- 497 63 Silva, G. G. Z. *et al.* Combining de novo and reference-guided assembly with scaffold_builder.
498 *Source Code for Biology and Medicine* **8**, 23, doi:10.1186/1751-0473-8-23 (2013).
- 499 64 Thompson, J. D., Higgins, D. G. & Gibson, T. J. CLUSTAL W: improving the sensitivity of
500 progressive multiple sequence alignment through sequence weighting, position-specific gap
501 penalties and weight matrix choice. *Nucleic Acids Res* **22**, 4673-4680,
502 doi:10.1093/nar/22.22.4673 (1994).
- 503 65 Waterhouse, A. *et al.* SWISS-MODEL: homology modelling of protein structures and
504 complexes. *Nucleic Acids Res* **46**, W296-W303, doi:10.1093/nar/gky427 (2018).
- 505

506 **Methods**

507 **Enrolment of FIP cases in Cyprus**

508 The electronic records of Vet Dia Gnosis in Limassol, Cyprus were searched for any positive FCoV
509 RT-PCR cases from September 2021 up to August 2023. The cases to be enrolled needed to have
510 compatible clinicopathological findings for FIP as recently outlined by the European Advisory
511 Board on Cat Diseases Guidelines²⁵ as well having a positive RT-PCR for FCoV in one of the
512 following samples: peritoneal fluid, pleural fluid, cerebrospinal fluid and granuloma fine needle
513 aspiration biopsies or tissue biopsies. The original samples were submitted to the Vet Dia Gnosis
514 commercial laboratory (Limassol, Cyprus) by local veterinarians and then submitted to
515 LABOKLIN commercial laboratory (Bad Kissingen, Germany). Ethical approval for this study was
516 granted by the Pancyprian Vet Association. According to the terms and conditions of the Vet Dia
517 Gnosis, as well as the Cypriot legislation [The Dogs LAW, N. 184 (I)/2002], no special permission
518 from animal owners or the animal welfare commission is needed for additional testing on residual
519 sample material once diagnostics are completed. According to the terms and conditions of the
520 LABOKLIN laboratory, as well as the RUF-55.2.2.2532-1-86-5 decision of the government of
521 Lower Franconia, no special permission from animal owners or the animal welfare commission
522 is needed for additional testing on residual sample material once diagnostics are completed.

523 **Sample from cat imported to the UK**

524 Two UK veterinary practices contacted the Royal Dick School of Veterinary Sciences (R(D)SVS)
525 with suspected cases of FIP in cats recently imported from Cyprus. Peritoneal fluid samples were
526 taken from the cats and sent to R(D)SVS for further testing and for sequencing at The Roslin
527 Institute with the consent of the cats' owners. The veterinary practices and the cats' owners were
528 kept informed at all stages.

529 **Histopathology and immunohistochemistry**

530 A sub-set of cases (n=4) from the FIP cats diagnosed after January 2023 with available tissue
531 specimens were selected. Tissue specimens were carefully obtained and immediately fixed in
532 10% buffered formalin. Following fixation, the tissues were processed by embedding, 4µm
533 sectioning, and subsequent staining with hematoxylin and eosin (H&E). The inclusion criteria
534 were defined based on comprehensive histopathological assessments. Specifically, emphasis was
535 placed on identifying the characteristic FIP-associated histological hallmarks, which
536 encompassed vasculitis, phlebitis, and periphlebitis. Consecutive tissue sections were mounted
537 onto charged slides. Following pre-treatment for 5 min at 110°C in 0.01M pH 6 citrate buffer,
538 slides were incubated for 30 min at room temperature with primary mouse monoclonal anti-
539 feline coronavirus antibody at 1:400 (BioRad, MCA 2194). The EnVision anti-mouse system was
540 used for visualization according to the manufacturer's instructions (Agilent).

541 **RNA extraction and cDNA synthesis**

542 RNA from specimens from Cyprus underwent automated total nucleic acid extraction using the
543 MagNA Pure 96 DNA AND Viral NA Small Volume kit (Roche Diagnostics). RT-PCR for FCoV was
544 performed at Laboklin Bad Kissingen, Germany⁵⁰.

545 RNA samples from cats imported to the UK from Cyprus were extracted using the QIAamp viral
546 RNA extraction kit (Qiagen) according to the manufacturer's instructions.

547 cDNA synthesis on all RNA samples was carried out using LunaScript RT SuperMix Kit (NEB) with
548 16 µl template RNA in 20 µl reactions according to the manufacturer's instructions.

549 **Primer design and PCR amplification**

550 A set of primers for 1kb tiled amplification were designed initially using primalscheme⁵¹ with
551 available FCoV genomes on NCBI⁵², and then by manual redesigns. Currently there is not a
552 working scheme for the entire genome, however, through multiple redesigns on multiple samples
553 it was possible to amplify sections which, when combined, cover the entire genome with one gap.
554 It should be noted that sequences obtained from this process do not all originate from the same
555 sample, and the genome assembled from these is representative at a population level rather than
556 an individual level, and therefore may not accurately represent virus present within an individual.
557 Efforts are ongoing to create a working tiled amplification scheme. The primer sequences used
558 here are in Supplementary Table 18. The PCRs for these multiplexed amplifications used the same
559 conditions described below, but with multiplexed primers.

560 DNA was amplified using primers targeting the majority of the spike region and incorporating a
561 flanking region of known FCoV sequence, with an expected amplicon size of around 3.7 kb. These
562 were designed based on previously amplified flanking sequences during the tiled amplification
563 design process: forward primer 5'-GACGCAGACTTCAGTGTTA-3'; and reverse primer 5'-
564 ACCATTATGCCATTRTARTA-3'. These primers do also produce offtarget amplification of the
565 feline growth hormone receptor. Additional amplicons designed during the tiled amplicon
566 designing process were used to amplify regions of POL1ab and Orf3c/E/M from the samples
567 (Supplementary Table 18).

568 PCR amplification was carried out on each sample using VeriFi Hot Start Mix (PCR Biosystems),
569 1.25µl 10µM forward and reverse primers and 2µl cDNA in a 25µl reaction. Amplification was
570 performed with the following PCR conditions: initial denaturation at 95°C for 1 minute, then 35
571 cycles of denaturation at 95°C for 15 seconds, annealing at 52°C for 15 seconds, extension at 72°C
572 for 4 minutes, followed by a final extension at 72°C for 5 minutes. Amplified DNA was purified
573 using AMPure XP beads (Beckman Coulter). The amplicons targeting POL1ab and NSP3c/E/M

574 were amplified in a pool with other primer pairs using the same PCR conditions but with 4µl cDNA
575 in the reaction instead of 2µl.

576 **Nanopore sequencing**

577 Amplicons were quantified using Qubit (Thermo Fisher) High Sensitivity assays and diluted to
578 150ng DNA per sample in 12µl nuclease-free water. Libraries were prepared using Oxford
579 Nanopore Technologies' (ONT) NBD112.96 ligation kit following the manufacturer's protocol for
580 amplicon sequencing with some modifications. Due to unavailability of NBD112.96 kit reagent
581 AMII H, following ligation of barcodes a second end-prep was carried out using the Ultra II End
582 Repair module (NEB). The rest of the protocol was carried out from the adapter ligation stage as
583 per manufacturer's protocol for LSK112 using the AMX-F adapter supplied in the early access
584 Q20+ version of kit 112. The library was loaded onto a MinION R10.4 flow cell and sequencing
585 was carried out on a GridION sequencing device.

586 In order to identify the virus present in one of the UK cases as quickly as possible, only the spike
587 amplicon was amplified and the sample sequenced using ONT RAD004 rapid sequencing kit on
588 an R9.4 flow cell following manufacturer's protocol. The other UK case was amplified at an earlier
589 time and was included in a sequencing run with the Cypriot samples, the data from that sample
590 was treated in the same way as the Cypriot samples and was the sample later found to have the
591 non-recombinant FCoV spike.

592 **Bioinformatic analysis**

593 Basecalling and demultiplexing was carried out on the GridION sequencing device (ONT) using
594 Guppy (v2.24-r1122) on super accurate mode, specifying --require_barcodes_both_ends and
595 using appropriate super accurate basecalling models for each of the different sequencing
596 methods used. Following basecalling, amplicon_sorter⁵³ (v2023-06-19) was used to identify
597 consensus amplicons between 3kb and 5kb without using a reference. Spike amplicons were
598 identified from the output via alignment with minimap2⁵⁴ (v2.22) to the spike from the first
599 sample we sequenced (Cypriot_G7_Gi_6739) for which a consensus was made using the same
600 process, with the correct amplicon identified via BLAST⁵⁵. The identified amplicons were polished
601 with medaka (v1.8.0, ONT). For the UK case which was sequenced with the rapid kit, because the
602 reads were fragmented by the library prep process, reads were used to polish the
603 Cypriot_G7_Gi_6739 sequence using medaka. The reads were aligned to the polished sequence
604 with minimap2 and visualized with IGV⁵⁶ (v2.11.1) to visually confirm the reads supported the
605 consensus sequence and that it had not been biased by the reference used. The amplicons in
606 POL1ab and Orf3c/E/M were assembled and polished using LILO⁵⁷. Multisequence alignments
607 were carried out for each of the regions using mafft⁵⁸ (v7.49) against all complete genomes of
608 CCoV and FCoV genomes available on NCBI using the --adjustdirection flag. Alignments were

609 visualized in Mega7⁵⁹ and sequences with poor sequencing quality were removed. All
610 downloaded genomes were trimmed down to each of the target regions amplified from our
611 samples. Maximum likelihood trees were constructed using IQ-TREE⁶⁰ (v2.0.5). TempEst⁶¹
612 (v1.5.3) was used to determine the best fitting root for the trees, and visualizations and
613 annotations of the trees were done using iTOL⁶² (v6.8.1). The trees were combined into figures
614 using BioRender.

615 To assemble a representative genome for the population, all of the samples for which we had
616 sequencing data were run through LILO. The polished amplicons were mapped to a single fasta
617 file containing an FCoV (MT239440.1) and a CCoV (KP981644.1) using minimap2 and
618 visualized with IGV, with only the amplicons from the spike region aligning to CCoV.
619 Representative amplicons covering the entire genome were selected and scaffolded using
620 scaffold_builder⁶³ with MT239440.1 as a reference. The raw reads were trimmed by 50bp to
621 remove adapters and barcodes and they were used to polish this scaffold using medaka. Mafft
622 was used to align this genome to representative genomes from *Alphacoronavirus 1* with Canine
623 Respiratory Coronavirus as an outgroup, and Mega7 was used to create a neighbour join tree
624 which was visualized and annotated with iTOL. BLAST was used to align reads that span the gap
625 to existing CCoV and FCoV genomes to determine the likely breakpoint (results in Supplementary
626 Figure 6).

627 A multisequence alignment between the genome and MT239440.1, LC742526.1 and KP981644.1
628 was carried out using ClustalW⁶⁴ in Mega7, and recombination analysis carried out using RDP5³⁶
629 (v.5.45) on default settings.

630 **Structure prediction of spike deletion variants**

631 SWISS-MODEL structure prediction and analysis (<https://swissmodel.expasy.org/>, accessed
632 October 2023)⁶⁵ were used to model the partial, high confidence N-terminal sequence of a
633 full-length spike (1008aa) and a deletion spike (797aa). To model the G8 Cypriot full-length spike,
634 we used the alphacoronavirus 1 experimentally resolved CCoV-HuPn-2018³⁹ structure as a
635 template. Modelling against the 7usa.1.a, swung out confirmation, yielded GMQE 0.60 and Global
636 QMEAND of 0.68±0.05 with a sequence identity of 88.97% and against 7us6.1.A, proximal
637 confirmation, yielded GMQE of 0.62 and Global QMEAND of 0.58±0.05 with a sequence identity of
638 81.03%. Modelling of C10 spike, C-terminal deletion, against 7usa.1.A, swung out confirmation,
639 yielded GMQE 0.74 and Global QMEAND of 0.69±0.05 with a sequence identity of 88.66% and
640 against 7us6.1.A, proximal confirmation of HuPN, yielded GMQE of 0.76 and Global QMEAND of
641 0.70±0.05 with a sequence identity of 88.42%.

642 The receptor binding domain was modelled using the 7u0I.1B structure, again CCoV-HuPn-
643 2018³⁹ complexed with canine APN as a template. GMQE was 0.89 and Global QMEAND 0.85 ± 0.07
644 with a sequence identity of 92.41%. PDB files are available in the supplementary materials.